vs
AIM ImmunoTech Inc.（AIM）与Alector, Inc.（ALEC）财务数据对比。点击上方公司名可切换其他公司
Alector, Inc.的季度营收约是AIM ImmunoTech Inc.的297.0倍（$6.2M vs $21.0K）。Alector, Inc.净利率更高（-597.5% vs -19881.0%，领先19283.4%）。AIM ImmunoTech Inc.同比增速更快（-53.3% vs -88.5%）。过去两年AIM ImmunoTech Inc.的营收复合增速更高（-27.5% vs -37.4%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
AIM vs ALEC — 直观对比
营收规模更大
ALEC
是对方的297.0倍
$21.0K
营收增速更快
AIM
高出35.2%
-88.5%
净利率更高
ALEC
高出19283.4%
-19881.0%
两年增速更快
AIM
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $6.2M |
| 净利润 | $-4.2M | $-37.3M |
| 毛利率 | — | — |
| 营业利润率 | -14057.1% | -634.4% |
| 净利率 | -19881.0% | -597.5% |
| 营收同比 | -53.3% | -88.5% |
| 净利润同比 | 30.0% | -1696.9% |
| 每股收益（稀释后） | $-6.46 | $-0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMALEC
| Q4 25 | $21.0K | $6.2M | ||
| Q3 25 | $26.0K | $3.3M | ||
| Q2 25 | $25.0K | $7.9M | ||
| Q1 25 | $16.0K | $3.7M | ||
| Q4 24 | $45.0K | $54.2M | ||
| Q3 24 | $35.0K | $15.3M | ||
| Q2 24 | $50.0K | $15.1M | ||
| Q1 24 | $40.0K | $15.9M |
净利润AIMALEC
| Q4 25 | $-4.2M | $-37.3M | ||
| Q3 25 | $-3.3M | $-34.7M | ||
| Q2 25 | $-2.8M | $-30.5M | ||
| Q1 25 | $-3.7M | $-40.5M | ||
| Q4 24 | $-6.0M | $-2.1M | ||
| Q3 24 | $-3.7M | $-42.2M | ||
| Q2 24 | $-1.8M | $-38.7M | ||
| Q1 24 | $-5.8M | $-36.1M |
营业利润率AIMALEC
| Q4 25 | -14057.1% | -634.4% | ||
| Q3 25 | -9411.5% | -1153.6% | ||
| Q2 25 | -10584.0% | -433.6% | ||
| Q1 25 | -22618.8% | -1216.5% | ||
| Q4 24 | -13011.1% | -13.4% | ||
| Q3 24 | -12825.7% | -315.7% | ||
| Q2 24 | -7388.0% | -302.4% | ||
| Q1 24 | -14335.0% | -275.0% |
净利率AIMALEC
| Q4 25 | -19881.0% | -597.5% | ||
| Q3 25 | -12630.8% | -1063.4% | ||
| Q2 25 | -11176.0% | -387.7% | ||
| Q1 25 | -23156.3% | -1101.6% | ||
| Q4 24 | -13260.0% | -3.8% | ||
| Q3 24 | -10571.4% | -275.2% | ||
| Q2 24 | -3672.0% | -256.4% | ||
| Q1 24 | -14542.5% | -227.0% |
每股收益（稀释后）AIMALEC
| Q4 25 | $-6.46 | $-0.34 | ||
| Q3 25 | $1.57 | $-0.34 | ||
| Q2 25 | $-3.68 | $-0.30 | ||
| Q1 25 | $-0.05 | $-0.41 | ||
| Q4 24 | $-21.80 | $-0.02 | ||
| Q3 24 | $-6.00 | $-0.43 | ||
| Q2 24 | $-3.00 | $-0.40 | ||
| Q1 24 | $-0.12 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $256.0M |
| 总债务越低越好 | $4.5M | $10.0M |
| 股东权益账面价值 | $-9.8M | $30.6M |
| 总资产 | $5.8M | $293.2M |
| 负债/权益比越低杠杆越低 | — | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资AIMALEC
| Q4 25 | $3.0M | $256.0M | ||
| Q3 25 | $2.4M | $291.1M | ||
| Q2 25 | $835.0K | $307.3M | ||
| Q1 25 | $2.2M | $354.6M | ||
| Q4 24 | $4.0M | $413.4M | ||
| Q3 24 | $7.2M | $457.2M | ||
| Q2 24 | $10.1M | $503.3M | ||
| Q1 24 | $10.9M | $562.1M |
总债务AIMALEC
| Q4 25 | $4.5M | $10.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | $10.0M | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
股东权益AIMALEC
| Q4 25 | $-9.8M | $30.6M | ||
| Q3 25 | $-6.1M | $57.7M | ||
| Q2 25 | $-6.5M | $71.2M | ||
| Q1 25 | $-3.9M | $94.6M | ||
| Q4 24 | $-1.3M | $126.8M | ||
| Q3 24 | $2.9M | $118.9M | ||
| Q2 24 | $6.1M | $150.6M | ||
| Q1 24 | $4.8M | $178.9M |
总资产AIMALEC
| Q4 25 | $5.8M | $293.2M | ||
| Q3 25 | $5.5M | $335.3M | ||
| Q2 25 | $4.1M | $356.4M | ||
| Q1 25 | $6.2M | $408.3M | ||
| Q4 24 | $8.6M | $468.3M | ||
| Q3 24 | $13.6M | $516.0M | ||
| Q2 24 | $15.7M | $570.7M | ||
| Q1 24 | $16.2M | $635.5M |
负债/权益比AIMALEC
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $-41.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AIMALEC
| Q4 25 | $-2.0M | $-41.7M | ||
| Q3 25 | $-5.1M | $-32.5M | ||
| Q2 25 | $-1.5M | $-49.0M | ||
| Q1 25 | $-2.4M | $-60.8M | ||
| Q4 24 | $-4.0M | $-55.0M | ||
| Q3 24 | $-3.1M | $-50.7M | ||
| Q2 24 | $-3.0M | $-62.8M | ||
| Q1 24 | $-4.8M | $-61.3M |
自由现金流AIMALEC
| Q4 25 | — | — | ||
| Q3 25 | — | $-32.5M | ||
| Q2 25 | — | $-49.1M | ||
| Q1 25 | — | $-60.8M | ||
| Q4 24 | — | $-55.2M | ||
| Q3 24 | — | $-50.9M | ||
| Q2 24 | — | $-63.1M | ||
| Q1 24 | — | $-61.9M |
自由现金流率AIMALEC
| Q4 25 | — | — | ||
| Q3 25 | — | -997.6% | ||
| Q2 25 | — | -623.0% | ||
| Q1 25 | — | -1655.0% | ||
| Q4 24 | — | -101.8% | ||
| Q3 24 | — | -332.1% | ||
| Q2 24 | — | -418.6% | ||
| Q1 24 | — | -389.3% |
资本支出强度AIMALEC
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 3.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
